# Protocolized REDUction of Non‐Resuscitation Fluids in SEptic Shock Patients. A Protocol for the REDUSE Randomized Clinical Trial

**Authors:** Peter Bentzer, Anja Lindén, Markus H. Olsen, Gisela Lilja, Jane Fisher, Fredrik Sjövall, Thomas Kander, Maria Lengquist, Line Samuelsson, Johan Undén, Ewa Palmnäs, Jonatan Oras, Maria Cronhjort, Anca Balintescu, Alicia Lind, Björn Ahlström, Maria Meirik, Johanna Savilampi, Pirkka Pekkarinen, Anna Berggren, Nicklas Oscarsson, Mohammed Said, Markus Castegren, Susanne Faria, Linn Hemberg, Adam Linder, Miklos Lipcsey, Marcus B. Skrifvars, Matt P. Wise, Niklas Nielsen, Janus C. Jakobsen

PMC · DOI: 10.1111/aas.70095 · Acta Anaesthesiologica Scandinavica · 2025-07-16

## TL;DR

This study tests if limiting non-resuscitation fluids in septic shock patients improves survival and reduces complications compared to usual care.

## Contribution

A clinical trial protocol to evaluate restrictive fluid administration in septic shock patients for better outcomes and reduced complications.

## Key findings

- The trial will assess 90-day mortality as the primary outcome.
- Complications like acute kidney injury and cognitive function will be evaluated.
- Environmental impact of the interventions will also be measured.

## Abstract

In septic shock, administration of large fluid volumes is associated with poor outcomes. Recent evidence shows that non‐resuscitation fluids are the major modifiable source of fluids for patients with septic shock in intensive care units (ICUs). This clinical trial is designed to test the hypothesis that restrictive administration of non‐resuscitation fluids improves outcomes compared to usual care. Adult patients admitted to ICUs with septic shock will be randomly assigned within 12 h of admission to receive protocolized restrictive administration of non‐resuscitation fluids or usual care. The primary outcome is all‐cause mortality at 90 days. Secondary outcomes are complications during ICU stay up to 90 days (defined as any acute kidney injury or cerebral, coronary, intestinal, or limb ischemia), mechanical ventilation free days within 90 days, and for survivors cognitive function (by the Montreal Cognitive Assessment [MOCA‐BLIND]) and Health‐Related Quality of Life (by the EQ Visual Analogue Scale [EQ‐VAS]), both at 6 months. In addition, the climate impact of the interventions will be assessed. To detect an absolute reduction in mortality of 7.5%, with an alpha of 5% and a power of 90%, we aim to include 1850 patients. The trial is approved by the Swedish Ethical Review Authority. Results of primary and secondary clinical outcomes and the environmental outcome will be submitted for publication in a peer‐reviewed journal.

Trial Registration: NCT06140147.

## Full-text entities

- **Diseases:** SEptic Shock (MESH:D012772), acute kidney injury (MESH:D058186), cerebral, coronary, intestinal, or limb ischemia (MESH:D002545)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12267905/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12267905/full.md

## References

38 references — full list in the complete paper: https://tomesphere.com/paper/PMC12267905/full.md

---
Source: https://tomesphere.com/paper/PMC12267905